After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced preclinical data highlighting an ...

Responses observed in patients with and without previous exposure to other KRAS G12C inhib ...

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK ...

AbbVie is setting up a shot to buy Kestrel Therapeutics down the line, as the biotech doses patients in a Phase 1 trial for ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution ...

Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors ...

BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell lines, offering ...

Amgen Inc. AMGN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and has recommended conditional marketing ...